Interaction between cell and extracellular matrix in heart disease: Multiple roles of tenascin-C in tissue remodeling

Histology and Histopathology

Volumn 19, Issue 2, 2004, Pages 517-525

  Imanaka Yoshida, Kyoko ^a   Hiroe, M ^b   Yoshida, T ^a  

^a MIE UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE   (Japan)

Author keywords

Extracellular matrix; Fibrosis; Myocardial infarction; Myocarditis; Remodeling; Tenascin C

Indexed keywords

CELL MARKER; MATRIX METALLOPROTEINASE; TENASCIN;

ANGIOGENESIS; CELL DIFFERENTIATION; CELL FUNCTION; CELL INTERACTION; DISEASE ACTIVITY; EMBRYO DEVELOPMENT; EXTRACELLULAR MATRIX; HEART DISEASE; HEART INFARCTION; HEART MUSCLE; HEART MUSCLE CELL; HEART MUSCLE FIBROSIS; HEART VENTRICLE REMODELING; HUMAN; INFLAMMATION; MYOCARDIAL DISEASE; NONHUMAN; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; REVIEW;

ANIMALS; CELL ADHESION; EXTRACELLULAR MATRIX; FIBROSIS; HEART DISEASES; HUMANS; MODELS, ANATOMIC; MYOCARDIAL INFARCTION; MYOCARDITIS; MYOCYTES, CARDIAC; TENASCIN; WOUND HEALING;

EID: 1842454323     PISSN: 02133911     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (103)

1. Aziz S.M., Toborek M., Hennig B., Mattson M.P., Guo H., Lipke D.W. (1997). Oxidative stress mediates monocrotaline-induced alterations in tenascin expression in pulmonary artery endothelial cells. Int. J. Biochem. Cell Biol. 29, 775-787.
2. Barnea G., Grumet M., Milev P., Silvennoinen O., Levy J.B., Sap J. and Schlessinger J. (1994). Receptor tyrosine phosphatase beta is expressed in the form of proteoglycan and binds to the extracellular matrix protein tenascin. J. Biol. Chem. 269, 14349-14352.
3. Bornstein P. (1995). Diversity of function is inherent in matricellular proteins: An appraisal of thrombospondin 1. J. Cell Biol. 130, 503-506.
4. Bornstein P. and Sage E.H. (2002). Matricellular proteins: extracellular modulators of cell function. Curr. Opin. Cell Biol. 14, 608-616.
5. Braunwald E. and Bristow M.R. (2000). Congestive heart failure: Fifty years of progress. Circulation 102, IV14-23
6. Chiquet M. (1999). Regulation of extracellular matrix gene expression by mechanical stress. Matrix Biol. 18, 417-426.
7. Chiquet M. and Fambrough D.M. (1984). Chick myotendinous antigen. II. A novel extracellular glycoprotein complex consisting of large disulfide-linked subunits. J. Cell Biol. 98, 1937-1946.
8. Chiquet M., Renedo A.S., Huber F. and Fluck M. (2003). How do fibroblasts translate mechanical signals into changes in extracellular matrix production? Matrix Biol. 22, 73-80.
9. Chiquet-Ehrismann R. and Chiquet M. (2003). Tenascins: regulation and putative functions during pathological stress. J. Pathol. 200, 488-499.
10. Chiquet-Ehrismann R., Mackie E.J., Pearson C.A. and Sakakura T. (1986). Tenascin: An extracellular matrix protein involved in tissue interactions during fetal development and oncogenesis. Cell 47, 131-139.
11. Chiquet-Ehrismann R., Matsuoka Y., Hofer U., Spring J., Bernasconi C. and Chiquet M. (1991). Tenascin variants: Differential binding to fibronectin and distinct distribution in cell cultures and tissues. Cell Regul. 2, 927-938.
12. Chiquet-Ehrismann R., Tannheimer M., Koch M., Brunner A., Spring J., Martin D., Baumgartner S. and Chiquet M. (1994). Tenascin-C expression by fibroblasts is elevated in stressed collagen gels. J. Cell Biol. 127, 2093-2101.
13. Chung C.Y. and Erickson H.P. (1994). Cell surface annexin II is a high affinity receptor for the alternatively spliced segment of tenascin-C. J. Cell Biol. 126, 539-548.
14. Chung C.Y., Zardi L. and Erickson H.P. (1995). Binding of tenascin-C to soluble fibronectin and matrix fibrils. J. Biol. Chem. 270, 29012-29017.
15. Chung C.Y., Murphy-Ullrich J.E. and Erickson H.P. (1996). Mitogenesis, cell migration, and loss of focal adhesions induced by tenascin-C interacting with its cell surface receptor, annexin II. Mol. Biol. Cell 7, 883-892.
16. Chung C.Y. and Erickson H.P. (1997). Glycosaminoglycans modulate fibronectin matrix assembly and are essential for matrix incorporation of tenascin-C. J. Cell Sci. 110, 1413-1419.
17. Clark R.A.F (1996) Wound Repair: Overview and general consideration. In: The molecular mechanism of wound repair. 2nd ed. Clark R.A.F (eds). Plenum Press. New York. pp 3-50.
18. Cohn J.N., Ferrari R. and Sharpe N.U. (2000). Cardiac remodeling-concepts and clinical implications: A consensus paper from an international forum on cardiac remodeling. J. Am. Coll. Cardiol. 35, 569-582
19. Cowan K.N., Jones P.L. and Rabinovitch M. (1999). Regression of hypertrophied rat pulmonary arteries in organ culture is associated with suppression of proteolytic activity, inhibition of tenascin-C, and smooth muscle cell apoptosis. Circ Res. 84, 1223-1233.
20. Danowski B.A., Imanaka-Yoshida K., Sanger J.M. and Sanger J.W. (1992). Costameres are sites of force transmission to the substratum in adult rat cardiomyocytes. J. Cell Biol. 118, 1411-1420.
21. Fischer D., Brown-Ludi M., Schulthess T. and Chiquet-Ehrismann R. (1997). Concerted action of tenascin-C domains in cell adhesion, anti-adhesion and promotion of neurite outgrowth. J. Cell Sci. 110, 1513-1522.
22. Forsberg E., Hirsch E., Frohlich L., Meyer M., Ekblom P., Aszodi A., Werner S. and Fassler R. (1996). Skin wounds and severed nerves heal normally in mice lacking tenascin-C. Proc. Natl. Acad. Sci. USA 93, 6594-6599.
23. Frangogiannis N.G., Shimoni S., Chang S., Ren G., Dewald O., Gersch C., Shan K., Aggeli C., Reardon M. and Letsou G.V.U. (2002a). Active interstitial remodeling: An important process in the hibernating human myocardium. J. Am. Coll. Cardiol. 39, 1468-1474
24. Frangogiannis N.G., Smith C.W. and Entman M.L. (2002b). The inflammatory response in myocardial infarction. Cardiovasc. Res. 53, 31-47.
25. Gabbiani G. (1998). Evolution and clinical implications of the myofibroblast concept. Cardiovasc. Res. 38, 545-548.
26. Gabbiani G. (2003). The myofibroblast in wound healing and fibrocontractive diseases. J. Pathol. 200, 500-503.
27. Gore-Hyer E., Shegogue D., Markiewicz M., Lo S., Hazen-Martin D., Greene E.L., Grotendorst G. and Trojanowska. M. (2002). TGF-beta and CTGF have overlapping and distinct fibrogenic effects on human renal cells. Am. J. Physiol. Renal Physiol. 283, F707-716.
28. Greenwood J.A. and Murphy-Ullrich J.E. (1998). Signaling of de-adhesion in cellular regulation and motility. Microsc. Res. Techniq.. 43, 420-432
29. Grumet M., Milev P., Sakurai T., Karthikeyan L., Bourdon M., Margolis R.K. and Margolis R.U. (1994). Interactions with tenascin and differential effects on cell adhesion of neurocan and phosphacan, two major chondroitin sulfate proteoglycans of nervous tissue. J. Biol. Chem. 269, 12142-12146.
30. Hanamura N., Yoshida T., Matsumoto E., Kawarada Y. and Sakakura T. (1997). Expression of fibronectin and tenascin-C mRNA by myofibroblasts, vasucular cells and epithelial cells in human colon adenomas and carcinomas. Int. J. Cancer. 73, 10-15
31. Harkonen E., Virtanen I., Linnala A., Laitinen L.L. and Kinnula V.L. (1995). Modulation of fibronectin and tenascin production in human bronchial epithelial cells by inflammatory cytokines in vitro. Am. J. Respir. Cell Mol. Biol. 13, 109-115.
32. Heeneman S., Cleutjens J.P., Faber B.C., Creemers E.E., van Suylen R.J., Lutgens E., Cleutjens K.B. and Daemen M.J. (2003). The dynamic extracellular matrix: Intervention strategies during heart failure and atherosclerosis. J. Pathol. 200, 516-525.
33. Huang W., Chiquet-Ehrismann R., Moyano J.V., Garcia-Pardo A. and Orend G. (2001). Interference of tenascin-C with syndecan-4 binding to fibronectin blocks cell adhesion and stimulates tumor cell proliferation. Cancer Res. 61, 8586-8594.
34. Imanaka-Yoshida K. (2000). The transmission of contractility through cell adhesion. Prog. Mol. Subcell. Biol. 25, 21-35.
35. Imanaka-Yoshida K., Danowski B.A., Sanger J.M. and Sanger J.W. (1996). Living adult rat cardiomyocytes in culture: Evidence for dissociation of costameric distribution of vinculin from costameric distributions of attachments. Cell Motil. Cytoskel. 33, 263-275.
36. Imanaka-Yoshida K., Enomoto-Iwamoto K., Yoshida T. and Sakakura T. (1999). Contraction force of cardiomyocytes is transmitted to the extracellular matrix through an attachment complex composed of vinculin, talin, integrin α6β1 and laminin. Cell Motil. Cytoskel. 42, 1-11.
37. Imanaka-Yoshida K., Hiroe M., Nishikawa T., Ishiyama S., Shimojo T., Ohta Y., Sakakura T. and Yoshida T. (2001a). Tenascin-C modulates adhesion of cardiomyocytes to extracellular matrix during tissue remodeling after myocardial infarction. Lab. Invest. 81, 1015-1024.
38. Imanaka-Yoshida K., Matusura R., Isaka N., Nakano T., Sakakura T- and Yoshida T. (2001b). Serial extracellular matrix changes in neointimal lesions of human coronary artery after percuatneous tansluminal coronary angioplasty: Clinical significance of early tenascin-C expression. Virchows Archiv. 439, 185-190.
39. Imanaka-Yoshida K., Hiroe M., Yasutomi Y., Toyozaki T., Tsuchiya T., Noda N., Maki S., Nishikawa T., Sakakura T. and Yoshida T. (2002). Tenascin-C is a useful marker for disease activity in myocarditis. J. Pathol. 197, 387-394.
40. Imanaka-Yoshida K., Matsumoto K., Hara M., Sakakura T., Yoshida T. (2003). The dinamic expression of tenascin-C and tenascin-X during early heart development. Differentiation 71, 291-298.
41. Izzard C.S. and Lochner L.R. (1980). Formation of cell-to-substrate contacts during fibroblast motility: An interference-reflexion study. J. Cell Sci. 42, 81-116.
42. Jarvinen T.A., Kannus P., Jarvinen T.L., Jozsa L., Kalimo H. and Jarvinen M. (2000). Tenascin-C in the pathobiology and healing process of musculoskeletal tissue injury. Scand. J. Med. Sci. Sports 10, 376-382.
43. Jarvinen T.A.H., Jozsa L., Kannus P., Jarvinen T.L.N., Hurme T., Kvist M., Pelto-Huikko M., Kalimo H. and Jarvinen M. (2003). Mechanical loading regulates the expression of tenascin-C in the myotendinous junction and tendon but does not induce de novo synthesis in the skeletal muscle. J Cell Sci. 116, 857-866.
44. Jian B., Jones P.L., Li Q., Mohler E.R., III, Schoen F.J. and Levy R.J. (2001a). Matrix metalloproteinase-2 is Associated with tenascin-C in calcific aortic stenosis. Am. J. Pathol. 159, 321-327.
45. Jian B., Jones P.L., Li Q., Mohler E.R., 3rd, Schoen F.J. and Levy R.J. (2001b). Matrix metalloproteinase-2 is associated with tenascin-C in calcific aortic stenosis. Am. J. Pathol. 159, 321-327.
46. Jones P.L., Crack J. and Rabinovitch M. (1997). Regulation of Tenascin-C, a vascular smooth muscle cell survival factor that interacts with the alpha v beta 3 Integrin to promote epidermal growth factor receptor phosphorylation and growth. J. Cell Biol. 139, 279-293.
47. Jones F.S. and Jones P.L. (2000a). The tenascin family of ECM glycoproteins: Structure, function, and regulation during embryonic development and tissue remodeling. Dev. Dyn. 218, 235-259.
48. Jones P.L. and Jones F.S. (2000b). Tenascin-C in development and disease: Gene regulation and cell function. Matrix Biol. 19, 581-596.
49. Kalembey I., Yoshida T., Iriyama K. and Sakakura T. (1997). Analysis of tenascin mRNA expression in the murine mammary gland from embryogenesis to carcinogenesis: An in situ hybridization study. Int. J. Dev. Biol. 41, 569-573.
50. Kalembeyi I., Inada H., Nishiura R., Imanaka-Yoshida K., Sakakura T. and Yoshida T. (2003). Tenascin-C upregulates matrix metalloproteinase-9 in breast cancer cells: Direct and synergistic effects with transforming growth factor. Int. J. Cancer 105, 53-60.
51. Katz A.M. (1989). Cardiac interstitium in health and disease: the fibrillar collagne network. J. Am. Coll. Cardiol. 13, 1657-1662.
52. Lal A., Peters H., St Croix B., Haroon Z.A., Dewhirst M.W., Strausberg R.L., Kaanders J.H., van der Kogel A.J. and Riggins G.J. (2001). Transcriptional response to hypoxia in human tumors. J. Natl. Cancer Inst. 93, 1337-1343.
53. Latijnhouwers M.A., Pfundt R., de Jongh G.J. and Schalkwijk J. (1998). Tenascin-C expression in human epidermal keratinocytes is regulated by inflammatory cytokines and a stress response pathway. Matrix Biol. 17, 305-316.
54. Lorell B.H. and Carabello B.A. (2000). Left ventricular hypertrophy: Pathogenesis, detection, and prognosis. Circulation 102, 470-479.
55. Mackie E.J., Scott-Burden T., Hahn A.W., Kern F., Bernhardt J., Regenass S., Weller A. and Buhler F.R. (1992). Expression of tenascin by vascular smooth muscle cells. Alterations in hypertensive rats and stimulation by angiotensin II. Am. J.Pathol. 141, 377-388.
56. Mackie E.J. and Tucker R.P. (1999). The tenascin-C knockout revisited. J. Cell Sci. 112, 3847-3853.
57. Makhluf H.A., Stepniakowska J., Hoffman S., Smith E., LeRoy E.C., Trojanowska M. (1996). IL-4 upregulates tenascin synthesis in scleroderma and healthy skin fibroblasts. J. Invest. Dermatol. 107, 856-859.
58. Manabe I., Shindo T. and Nagai R. (2002). Gene expression in fibroblasts and fibrosis: Involvement in cardiac hypertrophy. Circ. .Res. 91, 1103-1113.
59. Mann D.L. (2002). Inflammatory mediators and the failing heart: Past, present, and the foreseeable future. Circ Res. 91, 988-998.
60. Mann D.L. and Spinale F.G. (1998). Activation of matrix metalloproteinases in the failing human heart: Breaking the tie that binds. Circulation. 98, 1699-1702.
61. Matsushita T., Oyamada M., Fujimoto K., Yasuda Y., Masuda S., Wada Y., Oka T. and Takamatsu T. (1999). Remodeling of cell-cell and cell-extracellular matrix interactions at the border zone of rat myocardial infarcts. Circ. Res. 85, 1046-1055.
62. Midwood K.S and Schwarzbauer J.E. (2002). Tenascin-C modulates matrix contraction via focal adhesion kinase- and Rho-mediated signaling pathways. Mol. Biol.Cell. 13, 3601-3613.
63. Mikawa T., Cohen-Gould L. and Fischman D.A. (1992). Clonal analysis of cardiac morphogenesis in the chicken embryo using a replication-defective retrovirus. III: Polyclonal origin of adjacent ventricular myocytes. Dev. Dyn.. 195, 133-141.
64. Mikawa T. and Gourdie R.G. (1996). Pericardial mesoderm generates a population of coronary smooth muscle cells migrating into the heart along with ingrowth of the epicardial organ. Dev. Biol. 174, 221-232.
65. Milev P., Friedlander D.R., Sakurai T., Karthikeyan L., Flad M., Margolis R.K., Grumet M. and Margolis R.U. (1994). Interactions of the chondroitin sulfate proteoglycan phosphacan, the extracellular domain of a receptor-type protein tyrosine phosphatase, with neurons, glia, and neural cell adhesion molecules. J. Cell Biol. 127, 1703-1715.
66. Murphy-Ullrich, J.E. (2001). The de-adhesive activity of matricellular proteins: Is intermediate cell adhesion an adaptive state? J. Clin. Invest. 107, 785-790.
67. Murphy-Ullrich J.E., Lightner V.A., Aukhil I., Yan Y.Z., Erickson H.P. and Hook M. (1991). Focal adhesion integrity is downregulated by the alternatively spliced domain of human tenascin. J. Cell Biol. 115, 1127-1136.
68. Noda N., Minoura H., Nishiura R., Toyoda N., Imanaka-Yoshida K., Sakakura T. and Yoshida T. (2000). Expression of tenascin-C in stromal cells ot the murine uterus during early pregnancy: Induction by interleukin-1 alpha, prostaglandin E2 and prostaglandin F2 alpha. Biol. Reprod. 63, 1723-1730
69. Oberhauser A.F., Marszalek P.E., Erickson H.P. and Fernandez J.M. (1998). The molecular elasticity of the extracellular matrix protein tenascin. Nature 393, 181-185.
70. Orend G. and Chiquet-Ehrismann R. (2000). Adhesion modulation by antiadhesive molecules of the extracellular matrix. Exp. Cell Res. 261, 104-110.
71. Pardo J.V., Siliciano J.D. and Craig S.W. (1983). Vinculin is a component of an extensive network of myofibril-sarcolemma attachment regions in cardiac muscle fibers. J. Cell Biol. 97, 1081-1088.
72. Pfeffer M. and Braunwald E. (1990). Ventricular remodeling after myocardial infarction. Experimental observations and clinical implications. Circulation 81, 1161-1172.
73. Poelmann R., Gittenberger-de Groot A., Mentink M., Bokenkamp R. and Hogers B. (1993). Development of the cardiac coronary vascular endothelium, studied with antiendothelial antibodies, in chicken-quail chimeras. Circ. Res. 73, 559-568.
74. Powell D.W. (2000). Myofibroblasts: Paracrine cells important in health and disease. Trans. Am. Clin. Climatol Assoc. 111, 271-292.
75. Rettig W.J., Erickson H.P., Albino A.P. and Garin-Chesa P. (1994). Induction of human tenascin (neuronectin) by growth factors and cytokines: Cell type-specific signals and signalling pathways. J. Cell Sci. 107, 487-497.
76. Ross R.S.and Borg T.K. (2001). Integrins and the myocardium. Circ Res. 88, 1112-1119.
77. Saga Y., Yagi T., Ikawa Y. and Sakakura T. and Aizawa S. (1992). Mice develop normally without tenascin. Genes Dev. 6, 1821-1831
78. Sakai T., Ohta M., Furukawa Y., Saga Y., Aizawa S., Kawakatsu H. and Saito M. (1995). Tenascin-C induction by the diffusible factor epidermal growth factor in stromal-epithelial interactions. J. Cell. Physiol. 165, 18-29.
79. Salmivirta M., Elenius K., Vainio S., Hofer U., Chiquet-Ehrismann R., Thesleff I. and Jalkanen M. (1991). Syndecan from embryonic tooth mesenchyme binds tenascin. J. Biol. Chem. 266, 7733-7739.
80. Sato I. and Shimada K. (2001). Quantitative analysis of tenascin in chordae tendineae of human left ventricular papillary muscle with aging. Ann Anat. 183, 443-448.
81. 111In monoclonal antibody specific for tenascin-C. Circulation. 106, 1397-1402.
82. Serini G. and Gabbiani G. (1999). Mechanisms of myofibroblast activity and phenotypic modulation. Exp. Cell Res. 250, 273-283.
83. Sharifi B.G., LaFleur D.W., Pirola C.J., Forrester J.S. and Fagin J.A. (1992). Angiotensin II regulates tenascin gene expression in vascular smooth muscle cells. J. Biol. Chem. 267, 23910-23915.
84. Spinale F.G. (2002). Matrix metalloproteinases: Regulation and dysregulation in the failing heart. Circ. Res. 90, 520-530.
85. Stier C.T., Jr., Chander P.N. and Rocha R. (2002). Aldosterone as a mediator in cardiovascular injury. Cardiol. Rev. 10, 97-107.
86. Streuli C. (1999). Extracellular matrix remodelling and cellular differentiation. Curr. Opin. Cell Biol. 11, 634-640.
87. Sussman M.A., McCulloch A. and Borg T.K. (2002). Dance Band on the Titanic: Biomechanical Signaling in Cardiac Hypertrophy. Circ. Res. 91, 888-898
88. Sutton M.G. and Sharpe N. (2000). Left ventricular remodeling after myocardial infarction: Pathophysiology and therapy. Circulation 101, 2981-2988.
89. Tamura A., Kusachi S., Nogami K., Yamanishi A., Kajikawa Y., Hirohata S and Tsuji T. (1996). Tenascin expression in endomyocardial biopsy specimens in patients with dilated cardiomyopathy: Distribution along margins of fibrotic lesions. Heart 75, 291-294.
90. Tremble P., Chiquet-Ehrismann R. and Werb Z. (1994). The extracellular matrix ligands fibronectin and tenascin collaborate in regulating collagenase gene expression in fibroblasts. Mol.. Biol. Cell 5, 439-453.
91. Tsunoda T., Inada H., Kalembeyi I., Imanaka-Yoshida K., Sakakibara M., Okada R., Katsuta K., Sakakura T., Majima Y. and Yoshida T. (2003). Involvement of large tenascin-C splice variants in breast cancer progression. Am. J. Pathol. 162, 1857-1867.
92. Vaughan L., Huber S., Chiquet M. and Winterhalter K.H. (1987). A major, six-armed glycoprotein from embryonic cartilage. EMBO. J. 6, 349-353.
93. Vaughan L., Weber P., D'Alessandri L., Zisch A.H. and Winterhalter K.H. (1994). Tenascin-contactin/F11 interactions: A clue for a developmental role? Perspect. Dev. Neurobiol. 2, 43-52.
94. Virdis A. and Schiffrin E.L. (2003). Vascular inflammation: A role in vascular disease in hypertension? Curr. Opin. Nephrol. Hypertens. 12, 181-187.
95. Weber K.T., Pick R., Jalil J.E., Janicki J.S. and Carroll E.P. (1989). Patterns of myocardial fibrosis. J. Mol. Cell Cardiol. 21, 121-131.
96. Wenk M.B., Midwood K.S. and Schwarzbauer J.E. (2000). Tenascin-C suppresses Rho activation. J. Cell Biol. 150, 913-920.
97. Willems I.E., Arends J.W. and Daemen M.J. (1996). Tenascin and fibronectin expression in healing human myocardial scars. J. Pathol. 179, 321-325.
98. Yamada S., Ichida T., Matsuda Y., Miyazaki Y., Hatano T., Hata K., Asakura H., Hirota N., Geerts A. and Wisse E. (1992). Tenascin expression in human chronic liver disease and in hepatocellular carcinoma. Liver 12, 10-16.
99. Yamamoto K., Dang Q.N., Kennedy S.P., Osathanondh R., Kelly R.A. and Lee R.T. (1999). Induction of tenascin-C in cardiac myocytes by mechanical deformation. Role of reactive oxygen species. J. Biol. Chem. 274, 21840-21846.
100. Yamamoto K., Dang Q.N., Maeda Y., Huang H., Kelly R.A. and Lee R.T. (2001). Regulation of cardiomyocyte mechanotransduction by the cardiac cycle. Circulation 103, 1459-1464.
101. Yoshida T., Matsumoto E., Hanamura N., Kalembeyi I., Katsuta K., Ishihara A. and Sakakura T. (1997). Co-expression of tenascin and fibronectin in epithelial and stromal cells of benign lesions and ductal carcinomas in the human breast. J. Pathol. 182, 421-428.
102. Yoshida T., Yoshimura E., Numata H., Sakakura Y. and Sakakura T. (1999). Involvement of tenascin-C in proliferation and migration of laryngeal carcinoma cells. Virchows Arch. 435, 496-500.
103. Zagzag D., Shiff B., Jallo G.I., Greco M.A., Blanco C., Cohen H., Hukin J., Allen J.C. and Friedlander D.R. (2002). Tenascin-C promotes microvascular cell migration and phosphorylation of focal adhesion kinase. Cancer Res. 62, 2660-2668.